基努伦酸和促进依赖活动的突触消除在精神分裂症
Funda Orhan1, Susmita Malwade1, Neda Khanlarkhani1
1Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm (Orhan, Malwade, Khanlarkhani, Gkogka, Jungholm, Koskuvi, Schwieler, Jardemark, Erhardt, Engberg, Samudyata, Sellgren); Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm (Langeder); Neuroscience Center, HiLIFE, University of Helsinki, Helsinki (Koskuvi, Lehtonen, Tiihonen, Koistinaho); A.I. Virtanen Institute for Molecular Sciences (Lehtonen) and Department of Forensic Psychiatry (Tiihonen), University of Eastern Finland, Kuopio; Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services, Stockholm County Council, Stockholm (Tiihonen, Sellgren); Institute of Sport Science and Innovations, Lithuanian Sports University, Kaunas, Lithuania (Engberg).
在精神分裂症中,高氨酸 (KYNA) 驱使微质细胞吞突触. 抑制KYNA的产生可能会在这种神经发育障碍中防止突触损失.
科学领域:
- 神经科学是一个神经科学.
- 神经生物学 神经生物学 神经生物学
- 精神病学是一个精神病学.
背景情况:
- 精神分裂症是一种神经发育障碍,与过度的突触损失有关.
- 丁酸 (KYNA) 是托芬的代谢物,在精神分裂症中是升高的,可以诱导疾病的表型.
- 将KYNA与精神分裂症病理生理学和突触损失联系在一起的确切机制尚未完全理解.
研究的目的:
- 研究KYNA是否通过减少神经元活动来诱导微质介导的突触吞.
- 在患者衍生模型中探索KYNA,突触活动和微质功能之间的关系.
- 分析大规模的遗传和死后大脑数据,以确定其临床相关性.
主要方法:
- 利用患者衍生诱导的多能干细胞来创建神经元和微细胞培养物和前脑器官.
- 评估KYNA对突触活动和微质突触吸收的影响.
- 分析了大规模的转录,遗传和死后大脑数据集.
主要成果:
- 在患者衍生模型中,微质诱导了KYNA诱导的突触结构的吸收.
- 抑制内源KYNA的产生减少了微质突触的内部化.
- 产生KYNA的酶 (KATs) 与突触活动基因和精神分裂症遗传风险变异有关.
结论:
- 精神分裂症的遗传风险变异与KYNA产量升高有关.
- KYNA促进了微质体对活动依赖的突触物质的内化,有助于突触损失.
- 对KATs的药理抑制是减轻精神分裂症中突触损失的潜在策略.
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
Drugs Affecting Neurotransmitter Synthesis
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Antidepressant Drugs: MAOIs and Other Agents
Neurochemical Transmission: Sites of Drug Action


